The cost effectiveness of adalimumab (HUMIRA®) in UK patients with moderate to severe RA

被引：0

作者：

Bansback, NJ

Brennan, A

Sengupta, N

Pang, F

机构：

[1] Univ Sheffield, Sheffield, S Yorkshire, England

[2] Abbott Labs, Abbott Pk, IL 60064 USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：512 / 513

页数：2

共 50 条

[1] Cost effectiveness of adalimumab (HUMIRA™, Abbott) in the treatment of patients with moderate to severe rheumatoid arthritis (RA)
Bansback, NJ
Brennan, A
Sengupta, N
Chang, KY
ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S215 - S215
[2] The cost effectiveness of adalimumab (HUMIRA®) in patients with RA:: A Finnish analysis
Bansback, NJ
Brennan, A
Sengupta, N
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 513 - 514
[3] The cost-effectiveness of adalimumab (HUMIRA®) in patients with rheumatoid arthritis (RA) in Denmark
Aagren, M.
Davies, A.
Winding, B.
Cifaldi, M.
Pang, F.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 : 15 - 15
[4] THE COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRA™) IN PATIENTS WITH RHEUMATOID ARTHRITIS: A UK ANALYSIS
Bansback, N.
Brennan, A.
Sengupta, N.
Pang, F.
RHEUMATOLOGY, 2004, 43 : 77 - 77
[5] Cost-effectiveness of adalimumab (Humira™) in the treatment of US patients with rheumatoid arthritis (RA)
Bansback, N
Brennan, A
Sengupta, N
VALUE IN HEALTH, 2004, 7 (03) : 241 - 241
[6] Cost effectiveness of Adalimumab (HUMIRA®) plus Methotrexate vs. Etanercept (ENBREL) plus methotrexate in moderate to severe rheumatoid arthritis (RA)
Davies, AS
Hutton, J
Weisman, MH
Cifaldi, MA
Pang, F
Spencer-Green, GT
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 68 - 68
[7] The cost-utility of adalimumab (Humira) in patients with rheumatoid arthritis (RA) in Denmark
Aagren, M.
Davies, A.
Pang, F.
Winding, B.
VALUE IN HEALTH, 2006, 9 (06) : A223 - A223
[8] Subgroup analysis of radiographic progression in RA patients with moderate disease treated with adalimumab (Humira®)
Keystone, EC
Furst, DE
Kavanaugh, AF
Spencer-Green, GT
Szczerbak, NA
Mydler, TT
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 267 - 267
[9] Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden
Bansback, NJ
Brennan, A
Ghatnekar, O
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (07) : 995 - 1002
[10] Adalimumab (HUMIRA®) monotherapy significantly improves fatigue in patients with severe rheumatoid arthritis (RA)
Dietz, BM
Sterz, R
Holtbrügge, W
Kupper, H
Van de Putte, LBA
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 392 - +

← 1 2 3 4 5 →